Evaluating Treatment Strategies for Breast Cancer
Author Information
Author(s): Day R S, Shackney S E, Peters W P
Primary Institution: University of Pittsburgh
Hypothesis
What is the impact of dose intensification on relapse-free survival in breast cancer patients with positive axillary nodes?
Conclusion
The study suggests that treatment intensification may provide a modest benefit for patients with 10 or more positive axillary nodes, but much of this benefit could be achieved with intermediate levels of treatment.
Supporting Evidence
- 48% of tumors are estimated to be unresponsive to maximally intensive adjuvant treatment.
- The estimated log kill for intermediate-dose therapy was 6.5 logs.
- 5-year relapse-free survival was approximately 0.65 for high-dose patients.
Takeaway
This study looks at how different treatments for breast cancer can help patients stay cancer-free after surgery, especially for those with a lot of cancer in their lymph nodes.
Methodology
A mathematical model was developed to analyze the time to clinical tumor recurrence based on residual tumor burden and treatment intensity.
Potential Biases
Potential biases may arise from the assumptions regarding treatment response and the independence of tumor growth and residual burden.
Limitations
The model relies on several assumptions that may not hold true in all patient populations.
Participant Demographics
Patients included those with stage I–III breast cancer, specifically focusing on those with 10 or more positive axillary nodes.
Statistical Information
P-Value
0.17
Confidence Interval
29–67%
Statistical Significance
p=0.17
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website